Table 1.
Patient demographics and baseline characteristics
| Patient characteristics | N (30) | % |
|---|---|---|
| Median age, years (range) | 61 | (30–79) |
| Sex | ||
| Male | 17 | 57 |
| Female | 13 | 43 |
| ECOG Performance status | ||
| 0 | 18 | 60 |
| 1 | 12 | 40 |
| MMR status | ||
| pMMR | 21 | 70 |
| dMMR | 1 | 3 |
| Unknown | 8 | 27 |
| KRAS Mutation status | ||
| Mutated | 17 | 57 |
| Wild type | 11 | 37 |
| Unknown | 2 | 7 |
| BRAF Mutation status | ||
| V600E | 1 | 3 |
| Wild type | 20 | 67 |
| Unknown | 9 | 30 |
| Median lines of prior systemic therapy, lines (range) | 3 | (2–5) |
| 2 | 14 | 47 |
| 3 | 10 | 33 |
| 4 | 3 | 10 |
| 5 | 3 | 10 |
| Previous systemic therapy | ||
| FOLFOX + Bevacizumab | 21 | 70 |
| FOLFIRI + Bevacizumab | 18 | 60 |
| Regorafenib | 10 | 33 |
| FOLFOX | 6 | 20 |
| FOLFIRI + Ziv-aflibercept | 4 | 13 |
| FOLFIRI + Cetuximab | 3 | 30 |
| Other | 18 | 60 |